source
- AstraZeneca and Ionis report failure of eplontersen in ATTR-CM trialAstraZeneca and Ionis said their nucleic‑acid drug eplontersen did not meet the primary goal in a large study of patients with transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM). Over a 140‑we…
- GSK ends $2.2 billion brain drug partnership with Alector after trial failuresGSK and California‑based biotech Alector have ended their collaboration after both experimental brain drugs failed to meet development milestones. The partnership, announced in July 2021, gave GSK…